- Development of an ERG-preferred base case using “unblended” EMA-recommended treatment durations for LDV/SOF(+/-RBV)
- Examination of alternative EMA-recommended treatment durations for LDV/SOF
- Use of alternative transition probabilities based on the previous sofosbuvir STA model
- Use of UK valued on-treatment utility increment derived by Wright et al
- Use of shorter time horizons (5-years and 10-years) to dampen assumptions regarding no re-infection
- Threshold analysis for SVR rates of the comparators
The HEDS team were Praveen Thokala, Emma Simpson, Paul Tappenden and John Stevens.